.

Tecentriq (Atezolizumab) is a monoclonal antibody that belongs to a class of immune checkpoint inhibitors. It is designed to block the programmed death-ligand 1 (PD-L1) protein, enhancing the immune system's ability to detect and destroy cancer cells. Tecentriq is used in the treatment of various advanced cancers, including lung, liver, breast, and bladder cancers.

Indications:

Non-Small Cell Lung Cancer (NSCLC):

As a single agent or in combination with chemotherapy for advanced or metastatic cases.
Small Cell Lung Cancer (SCLC):

In combination with chemotherapy as first-line treatment for extensive-stage disease.
Triple-Negative Breast Cancer (TNBC):

In combination with nab-paclitaxel for PD-L1-positive, unresectable locally advanced, or metastatic disease.
Hepatocellular Carcinoma (HCC):

In combination with bevacizumab for patients with no prior systemic therapy.

Urothelial Carcinoma:

For patients with advanced or metastatic disease who are ineligible for cisplatin-containing chemotherapy.
Tecentriq works by inhibiting the PD-L1 protein on cancer cells, which normally binds to the PD-1 receptor on T-cells to suppress their activity. By blocking this interaction, Tecentriq restores T-cell activity, enabling the immune system to recognize and attack cancer cells.

Common Side Effects: Fatigue, Nausea, Diarrhea, Decreased appetite, Rash.

Serious Side Effects: 

Immune-Related Reactions: Pneumonitis (lung inflammation), Hepatitis (liver inflammation), Colitis (intestinal inflammation), Endocrinopathies (e.g., hypothyroidism, adrenal insufficiency).

Infusion Reactions: Fever, chills, and shortness of breath during infusion.

Severe Infections: Increased risk of infections due to immune modulation.

Standard Dose for Adults:

840 mg IV every 2 weeks, or
1,200 mg IV every 3 weeks, or
1,680 mg IV every 4 weeks.

Administration Tips:

Administer as an intravenous infusion over 60 minutes.
If well-tolerated, subsequent infusions can be reduced to 30 minutes.
Ensure pre-treatment screening for liver function, PD-L1 status, and overall patient health.